Analysts Expect PerkinElmer, Inc. (NYSE:PKI) to Announce $2.08 EPS

Brokerages expect PerkinElmer, Inc. (NYSE:PKIGet Rating) to announce earnings of $2.08 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for PerkinElmer’s earnings. The highest EPS estimate is $2.11 and the lowest is $2.05. PerkinElmer reported earnings of $3.72 per share in the same quarter last year, which would suggest a negative year over year growth rate of 44.1%. The firm is expected to issue its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that PerkinElmer will report full year earnings of $6.92 per share for the current financial year, with EPS estimates ranging from $6.85 to $6.97. For the next fiscal year, analysts forecast that the firm will report earnings of $7.14 per share, with EPS estimates ranging from $7.00 to $7.35. Zacks’ EPS averages are a mean average based on a survey of research firms that cover PerkinElmer.

PerkinElmer (NYSE:PKIGet Rating) last released its earnings results on Tuesday, February 1st. The medical research company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.15 by $0.41. The firm had revenue of $1.36 billion during the quarter, compared to analyst estimates of $1.32 billion. PerkinElmer had a net margin of 18.40% and a return on equity of 23.73%. The business’s revenue was up .7% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.96 EPS.

Separately, StockNews.com assumed coverage on shares of PerkinElmer in a research report on Thursday, March 31st. They set a “hold” rating for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $166.37.

In other news, insider Daniel R. Tereau sold 6,696 shares of the company’s stock in a transaction that occurred on Monday, March 14th. The stock was sold at an average price of $165.84, for a total value of $1,110,464.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.52% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of PKI. Amundi Pioneer Asset Management Inc. increased its holdings in PerkinElmer by 1.3% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 128,822 shares of the medical research company’s stock valued at $12,413,000 after purchasing an additional 1,695 shares in the last quarter. Kestra Advisory Services LLC increased its stake in shares of PerkinElmer by 29.2% in the third quarter. Kestra Advisory Services LLC now owns 2,106 shares of the medical research company’s stock valued at $365,000 after buying an additional 476 shares in the last quarter. Signaturefd LLC raised its holdings in shares of PerkinElmer by 11.1% in the third quarter. Signaturefd LLC now owns 1,803 shares of the medical research company’s stock valued at $312,000 after buying an additional 180 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in PerkinElmer by 6.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 16,157 shares of the medical research company’s stock worth $2,799,000 after buying an additional 1,023 shares in the last quarter. Finally, Banque Cantonale Vaudoise grew its holdings in PerkinElmer by 221.8% during the 3rd quarter. Banque Cantonale Vaudoise now owns 6,819 shares of the medical research company’s stock worth $1,182,000 after acquiring an additional 4,700 shares during the last quarter. 81.95% of the stock is currently owned by institutional investors and hedge funds.

Shares of PerkinElmer stock opened at $160.38 on Tuesday. The firm has a fifty day moving average price of $174.70 and a two-hundred day moving average price of $178.28. PerkinElmer has a fifty-two week low of $126.75 and a fifty-two week high of $203.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.01 and a quick ratio of 1.50. The company has a market cap of $20.23 billion, a PE ratio of 19.85, a price-to-earnings-growth ratio of 0.50 and a beta of 1.10.

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 13th. Stockholders of record on Friday, April 22nd will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 21st. This represents a $0.28 annualized dividend and a dividend yield of 0.17%. PerkinElmer’s dividend payout ratio (DPR) is currently 3.47%.

PerkinElmer Company Profile (Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

Featured Stories

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.